M.A.T.E. Module 1: Introduction to the MATE Act and the Role of Dexamethasone in Non
About This Event
Effective June 27, 2023 as a part of the Medication Access and Training Expansion (MATE) Act, the US Drug Enforcement Administration (DEA) requires that health practitioners who apply for or renew their Drug Enforcement Administration (DEA) registration to prescribe controlled substances must attest they have completed a one-time, eight-hour training by checking a box on their online DEA application form. The deadline for satisfying this new training requirement is the date of a practitioner’s initial application for DEA registration or their next scheduled DEA registration renewal. The intention of the MATE Act is standardizing substance use disorder (SUD) training and to ensure that all prescribers of addictive medications possess baseline knowledge in evidence-based addiction treatments and prevention. For dentists this one-time, eight-hour curriculum must address “safe pharmacological management of dental pain and screening, brief intervention, and referral for appropriate treatment of patients with or at risk of developing opioid and other substance use disorders.
This first module is designed to provide an overview of the MATE Act and discuss specifically what dentists need to do to comply with this requirement. In addition, a non-opioid post-operative analgesic strategy involving the glucocorticoid dexamethasone will be discussed.
Learning Objectives
- Discuss the history of the MATE Act
- Understand what topics and providers are approved
- Describe how non-opioid analgesics specifically ibuprofen, acetaminophen, and glucocorticoids could be as effective as opioid analgesics
- Explain how dexamethasone could be utilized to address post-operative pain, swelling, and trismus